Table 4.
The Difference of RAPSN Methylation Levels Between Female LC Cases and Controls by Quartile Analyses
| CpG Sites | Methylation | Control (N) | Case (N) | OR (95% CI) a | p-value |
|---|---|---|---|---|---|
| RAPSN_CpG_1.15 | Q4 (≥0.97) | 36 | 19 | 1.00 (reference) | - |
| Q3 (0.94–0.97) | 54 | 45 | 1.86 (0.88–3.93) | 0.105 | |
| Q2 (0.92–0.94) | 21 | 15 | 1.61 (0.64–4.05) | 0.313 | |
| Q1 (<0.92) | 29 | 21 | 1.47 (0.66–3.28) | 0.346 | |
| RAPSN_CpG_2 | Q4 (≥0.89) | 38 | 14 | 1.00 (reference) | - |
| Q3 (0.83–0.89) | 27 | 16 | 1.86 (0.76–4.56) | 0.174 | |
| Q2 (0.77–0.83) | 42 | 44 | 3.60 (1.60–8.08) | 0.002 | |
| Q1 (<0.77) | 33 | 26 | 2.49 (1.09–5.72) | 0.031 | |
| RAPSN_CpG_3.4 | Q4 (≥0.98) | 39 | 21 | 1.00 (reference) | - |
| Q3 (0.96–0.98) | 39 | 34 | 1.69 (0.83–3.44) | 0.151 | |
| Q2 (0.94–0.96) | 33 | 21 | 1.26 (0.57–2.76) | 0.564 | |
| Q1 (<0.94) | 29 | 24 | 1.59 (0.74–3.40) | 0.237 | |
| RAPSN_CpG_5 | Q4 (≥0.99) | 39 | 15 | 1.00 (reference) | - |
| Q3 (0.96–0.99) | 52 | 46 | 2.55 (1.21–5.35) | 0.014 | |
| Q2 (0.95–0.96) | 16 | 14 | 2.61 (0.99–6.85) | 0.052 | |
| Q1 (<0.95) | 33 | 25 | 2.11 (0.94–4.70) | 0.069 | |
| RAPSN_CpG_6 | Q4 (≥0.96) | 39 | 28 | 1.00 (reference) | - |
| Q3 (0.90–0.96) | 35 | 25 | 0.99 (0.49–2.01) | 0.976 | |
| Q2 (0.86–0.90) | 30 | 26 | 1.18 (0.57–2.45) | 0.651 | |
| Q1 (<0.86) | 35 | 21 | 0.83 (0.40–1.72) | 0.614 | |
| RAPSN_CpG_7.14 | Q4 (≥0.94) | 37 | 25 | 1.00 (reference) | - |
| Q3 (0.91–0.94) | 46 | 37 | 1.23 (0.61–2.45) | 0.564 | |
| Q2 (0.89–0.91) | 35 | 17 | 0.74 (0.33–1.64) | 0.461 | |
| Q1 (<0.89) | 22 | 21 | 1.42 (0.64–3.15) | 0.390 | |
| RAPSN_CpG_8 | Q4 (≥0.99) | 57 | 39 | 1.00 (reference) | - |
| Q3 (0.98–0.99) | 20 | 14 | 1.10 (0.48–2.54) | 0.825 | |
| Q2 (0.96–0.98) | 38 | 30 | 1.24 (0.63–2.45) | 0.540 | |
| Q1 (<0.96) | 25 | 17 | 1.01 (0.48–2.11) | 0.986 | |
| RAPSN_CpG_9 | Q4 (≥0.92) | 38 | 24 | 1.00 (reference) | - |
| Q3 (0.88–0.92) | 35 | 31 | 1.60 (0.76–3.36) | 0.213 | |
| Q2 (0.84–0.88) | 34 | 32 | 1.68 (0.81–3.48) | 0.165 | |
| Q1 (<0.84) | 33 | 13 | 0.61 (0.27–1.40) | 0.246 | |
| RAPSN_CpG_10.11 | Q4 (≥0.92) | 41 | 24 | 1.00 (reference) | - |
| Q3 (0.89–0.92) | 29 | 26 | 1.53 (0.74–3.19) | 0.255 | |
| Q2 (0.86–0.89) | 37 | 24 | 1.11 (0.54–2.30) | 0.774 | |
| Q1 (<0.86) | 33 | 26 | 1.35 (0.65–2.77) | 0.421 | |
| RAPSN_CpG_12 | Q4 (≥0.95) | 41 | 30 | 1.00 (reference) | - |
| Q3 (0.92–0.95) | 41 | 37 | 1.30 (0.66–2.53) | 0.447 | |
| Q2 (0.90–0.92) | 24 | 15 | 0.90 (0.40–2.06) | 0.807 | |
| Q1 (<0.90) | 34 | 18 | 0.73 (0.35–1.53) | 0.405 |
Note: alogistic regression adjusted for age, gender and experimental batches; p< 0.05 was considered as significant difference.
Abbreviations: LC, lung cancer; N, number; OR, odd ratio; CI, confidence interval.